Cancer Research and Treatment

Special Article

Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP: Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun Min Lim, Han Sang Kim, Choong-kun Lee, Jee Hung Kim, Sang Hoon Chun, Jina Yun, So Yeon Park, Hye Seung Lee, Yong Mee Cho, Soo Jeong Nam, Kiyong Na, Sun Och Yoon, Ahwon Lee, Kee-Taek Jang, Hongseok Yun, Sungyoung Lee, Jee Hyun Kim, Wan-Seop Kim; Cancer Res Treat. 2024;56(3):721-742. Published online November 29, 2023; DOI: https://doi.org/10.4143/crt.2023.1043

In recent years, next-generation sequencing (NGS)–based genetic testing has become crucial in cancer care. While its primary objective is to identify actionable genetic alterations to guide treatment decisions, its scope has broadened to encompass aiding in pathological diagnosis and exploring resistance mechanisms. With the ongoing expansion in NGS application and reliance, a compelling necessity arises for expert consensus on its application in solid cancers. To address this demand, the forthcoming recommendations not only provide pragmatic guidance for the clinical use of NGS but also systematically classify actionable genes based on specific cancer types. Additionally, these recommendations will incorporate expert perspectives on crucial biomarkers, ensuring informed decisions regarding circulating tumor DNA panel testing.

Citations

Citations to this article as recorded by

Real-World Data: Implementation and Outcomes of Next-Generation Sequencing in the MENA Region
Rami Mahfouz, Reine Abou Zeidane, Tasnim Diab, Ali Tarhini, Eman Sbaity, Houry Kazarian, Yomna El Zibaoui, Nour Sabiha Naji, Mounir Barake, Hazem I. Assi
Diagnostics.2025; 15(10): 1183. CrossRef
Exploring PIXE Applications in Oncology: A Comprehensive Review
G. J. Naga Raju
International Journal of Advanced Research in Science, Communication and Technology.2025; : 261. CrossRef

6,760 View
349 Download
1 Web of Science
2 Crossref

Original Articles

Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea: Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An; Cancer Res Treat. 2020;52(1):277-283. Published online July 12, 2019; DOI: https://doi.org/10.4143/crt.2019.292

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to evaluate clinical characteristics and treatment pattern of ovarian clear cell carcinoma (OCCC) in Korea and the role of adjuvant chemotherapy in early stage.
Materials and Methods
Medical records of 308 cases of from 21 institutions were reviewed and data including age, performance status, endometriosis, thromboembolism, stage, cancer antigen 125, treatment, recurrence, and death were collected.
Results
Regarding stage of OCCC, it was stage I in 194 (63.6%), stage II in 34 (11.1%), stage III in 66 (21.6%), and stage IV in 11 (3.6%) patients. All patients underwent surgery. Optimal surgery (residual disease ≤ 1 cm) was achieved in 89.3%. Majority of patients (80.5%) received postoperative chemotherapy. The most common regimen was taxane-platinum combination (96%). Median relapse-free survival (RFS) was 138.5 months for stage I, 33.4 for stage II, 19.3 for stage III, and 9.7 for stage IV. Median overall survival (OS) were not reached, 112.4, 48.7, and 18.3 months for stage I, II, III, and IV, respectively. Early-stage (stage I), endometriosis, and optimal debulking were identified as favorable prognostic factors for RFS. Early-stage and optimal debulking were also favorable prognostic factors for OS. Majority of patients with early-stage received adjuvant chemotherapy. However, additional survival benefit was not found in terms of recurrence.
Conclusion
Majority of patients had early-stage and received postoperative chemotherapy regardless of stage. Early-stage and optimal debulking were identified as favorable prognostic factors. In stage IA or IB, adding adjuvant chemotherapy did not show difference in survival. Further study focusing on OCCC is required.

Citations

Citations to this article as recorded by

Ovarian clear cell carcinoma: open questions on the management and treatment algorithm
Roberta Rosso, Margherita Turinetto, Fulvio Borella, Nicolas Chopin, Pierre Meeus, Alexandra Lainè, Isabelle Ray-Coquard, Olivia Le Saux, Domenico Ferraioli
The Oncologist.2025;[Epub] CrossRef
From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
Zesi Liu, Chunli Jing, Fandou Kong
Journal of Ovarian Research.2024;[Epub] CrossRef
SOX17 expression in ovarian clear cell carcinoma
Daichi Kodama, Motoki Takenaka, Chiemi Saigo, Masako Azuma, Yuki Hanamatsu, Masanori Isobe, Tamotsu Takeuchi
Journal of Ovarian Research.2024;[Epub] CrossRef
Construction of a Prediction Model of Cancer-Specific Survival after Ovarian Clear Cell Carcinoma Surgery
Mengqi Huang, Li Ling, Yanbo Liu, Yujuan Li
Clinical and Experimental Obstetrics & Gynecology.2024;[Epub] CrossRef
Patients with stage IA ovarian clear cell carcinoma do not require chemotherapy following surgery
Li Shuqing, Zhu Zhiling
Cancer Medicine.2023; 12(6): 6668. CrossRef
Clear cell carcinoma of the ovary and venous thromboembolism: a systematic review and meta-analysis
Hamidreza Didar, Farah Farzaneh, Hanieh Najafiarab, Kosar Namakin, Kimiya Gohari, Ali Sheidaei, Sepehr Ramezani
Current Medical Research and Opinion.2023; 39(6): 901. CrossRef
The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
Yuan Zhuang, Hua Yang
Cancer Control.2023;[Epub] CrossRef
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer
Satoe Fujiwara
Japanese Journal of Clinical Oncology.2023; 53(8): 664. CrossRef
Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
Yoo-Na Kim, Yun Soo Chung, Ji Hyun Lee, Eunhyang Park, Seung-Tae Lee, Sunghoon Kim, Jung-Yun Lee
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
Characteristics and Prognosis of Ovarian Pure Clear Cell Carcinoma: A Retrospective Experience of 136 Patients
Yang Gao, Wei Ding, Pengpeng Qu
Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
A clearer view on ovarian clear cell carcinoma
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys
Acta Clinica Belgica.2022; 77(4): 792. CrossRef
Friend or foe? The prognostic role of endometriosis in women with clear cell ovarian carcinoma. A UK population-based cohort study
Anastasios Tranoulis, Felicia Helena Buruiana, Bindiya Gupta, Audrey Kwong, Aarti Lakhiani, Jason Yap, Janos Balega, Kavita Singh
Archives of Gynecology and Obstetrics.2022; 305(5): 1279. CrossRef
Association Between Endometriosis and Prognosis of Ovarian Cancer: An Updated Meta-Analysis
Peng Chen, Chi-Yuan Zhang
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report
Abdulkarim Mohamed Farah, Shiyu Gu, Yan Jia
Medicine.2022; 101(37): e30666. CrossRef
Clear cell carcinoma of the ovary: a clinical and molecular perspective
Yasushi Iida, Aikou Okamoto, Robert L Hollis, Charlie Gourley, C Simon Herrington
International Journal of Gynecological Cancer.2021; 31(4): 605. CrossRef
Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study
Chenchen Zhu, Jing Zhu, Lili Qian, Hanyuan Liu, Zhen Shen, Dabao Wu, Weidong Zhao, Weihua Xiao, Ying Zhou
BMC Cancer.2021;[Epub] CrossRef
The oncological outcome of the patients with ovarian clear cell cancer: Platinum-based adjuvant chemotherapy is not suitable
Caner ÇAKIR, Fatih KILIÇ, Çiğdem KILIÇ, Dilek YÜKSEL, Vakkas KORKMAZ, Günsu KİMYON CÖMERT, Osman TÜRKMEN, Taner TURAN
Journal of Surgery and Medicine.2021; 5(8): 1. CrossRef
Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma
Qian Chen, Shu Wang, Jing-He Lang
Journal of Ovarian Research.2020;[Epub] CrossRef

9,549 View
432 Download
23 Web of Science
18 Crossref

A Case-Control Study to Identify Risk Factors for Totally Implantable Central Venous Port-Related Bloodstream Infection: Guk Jin Lee, Sook Hee Hong, Sang Young Roh, Sa Rah Park, Myung Ah Lee, Hoo Geun Chun, Young Seon Hong, Jin Hyoung Kang, Sang Il Kim, Youn Jeong Kim, Ho Jong Chun, Jung Suk Oh; Cancer Res Treat. 2014;46(3):250-260. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.250

Abstract PDF PubReader ePub

Purpose
To date, the risk factors for central venous port-related bloodstream infection (CVPBSI) in solid cancer patients have not been fully elucidated. We conducted this study in order to determine the risk factors for CVP-BSI in patients with solid cancer.
Materials and Methods
A total of 1,642 patients with solid cancer received an implantable central venous port for delivery of chemotherapy between October 2008 and December 2011 in a single center. CVP-BSI was diagnosed in 66 patients (4%). We selected a control group of 130 patients, who were individually matched with respect to age, sex, and catheter insertion time.
Results
CVP-BSI occurred most frequently between September and November (37.9%). The most common pathogen was gram-positive cocci (n=35, 53.0%), followed by fungus (n=14, 21.2%). Multivariate analysis identified monthly catheter-stay as a risk factor for CVP-BSI (p=0.000), however, its risk was lower in primary gastrointestinal cancer than in other cancer (p=0.002). Initial metastatic disease and long catheter-stay were statistically significant factors affecting catheter life span (p=0.005 and p=0.000). Results of multivariate analysis showed that recent transfusion was a risk factor for mortality in patients with CVP-BSI (p=0.047).
Conclusion
In analysis of the results with respect to risk factors, prolonged catheter-stay should be avoided as much as possible. It is necessary to be cautious of CVP-BSI in metastatic solid cancer, especially non-gastrointestinal cancer. In addition, avoidance of unnecessary transfusion is essential in order to reduce the mortality of CVP-BSI. Finally, considering the fact that confounding factors may have affected the results, conduct of a well-designed prospective controlled study is warranted.

Citations

Citations to this article as recorded by

A Comparative Study of Complications Related to Chemoport and Peripheral Line Among Cancer Patients Receiving Chemotherapy in Teaching Hospitals
Sucheta P. Yangad, Ceena Bjoy, Mayuri Shinde, Khurshid Jamadar, Sadhana Adhyapak, Ashwini Khochewad
Journal of Pharmacy and Bioallied Sciences.2025; 17(Suppl 2): S1197. CrossRef
Risk Factors of the Totally Implantable Venous Access Device-Related Infection in Patients With Brain Tumors Undergoing Chemotherapy After Surgery
Haihong Li, Jing Shan
Surgical Infections.2024; 25(2): 133. CrossRef
An analysis of totally implantable central venous port system infections in an urban tertiary referral center
Ulrich Krümpelmann, Ahmed Boseila, Mathias Löhnert, Olaf Kaup, Jacob J. Clarenbach, Martin Görner
Journal of Chemotherapy.2021; 33(4): 228. CrossRef
Use of catheter with 2-methacryloyloxyethyl phosphorylcholine polymer coating is associated with long-term availability of central venous port
Yuuki Iida, Kumiko Hongo, Takanobu Onoda, Yusuke Kita, Yukio Ishihara, Naoki Takabayashi, Ryo Kobayashi, Takeyuki Hiramatsu
Scientific Reports.2021;[Epub] CrossRef
Clinical Characteristics and Risk Factors of Long-term Central Venous Catheter–associated Bloodstream Infections in Children
Hye Min Moon, Suji Kim, Ki Wook Yun, Hyun-young Kim, Sung Eun Jung, Eun Hwa Choi, Hoan Jong Lee
Pediatric Infectious Disease Journal.2018; 37(5): 401. CrossRef
Risk factors for health care–associated infection in hospitalized adults: Systematic review and meta-analysis
Alba Luz Rodríguez-Acelas, Miriam de Abreu Almeida, Bruna Engelman, Wilson Cañon-Montañez
American Journal of Infection Control.2017; 45(12): e149. CrossRef
WITHDRAWN: Prevention of peripherally inserted central catheter-related infections in very low-birth-weight infants by using a central line bundle guideline with a standard checklist
Chen Yuan, Qing Zhao, Xiaoyan Song, Fei Meng
International Journal of Nursing Sciences.2016; 3(1): 50. CrossRef
Prevention of peripherally inserted central line-associated blood stream infections in very low-birth-weight infants by using a central line bundle guideline with a standard checklist: a case control study
Wei Wang, Chunling Zhao, Qinglian Ji, Ying Liu, Guirong Shen, Lili Wei
BMC Pediatrics.2015;[Epub] CrossRef
Central venous access in oncology: ESMO Clinical Practice Guidelines
B. Sousa, J. Furlanetto, M. Hutka, P. Gouveia, R. Wuerstlein, J.M. Mariz, D. Pinto, F. Cardoso
Annals of Oncology.2015; 26: v152. CrossRef
Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli
Jui-Feng Hsu, Hsu-Liang Chang, Ming-Ju Tsai, Ying-Ming Tsai, Yen-Lung Lee, Pei-Huan Chen, Wen-Chieh Fan, Yu-Chung Su, Chih-Jen Yang
World Journal of Surgical Oncology.2015;[Epub] CrossRef

13,811 View
124 Download
11 Web of Science
10 Crossref

Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee: Kyung A Kwon, Sung Yong Oh, Ho Young Kim, Hyo Song Kim, Ha Young Lee, Tae Min Kim, Ho Yeong Lim, Na-Ri Lee, Hyo Jin Lee, Sook Hee Hong, Sun Young Rha; Cancer Res Treat. 2014;46(2):141-147. Published online April 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.2.141

Abstract PDF PubReader ePub

Purpose

Collecting duct carcinoma (CDC) of the kidney is an aggressive disease with a poor prognosis, accountings for less than 1% of all renal cancers. To date, no standard therapy for CDC has been established. The aim of this study is an investigation of clinicopathologic findings of CDC and correlation of the disease status with a prognosis.

Materials and Methods

From 1996 to 2009, 35 patients with CDC were treated at eight medical centers. The diagnosis of CDC was made based on nephrectomy in 27 cases and renal biopsy in eight cases.

Results

Median PFS and OS for all patients were 5.8 months (95% CI 3.5 to 9.2) and 54.4 months (95% CI 0 to 109.2), respectively. The OS of patients with Stages I-III was 69.9 months (95% CI 54.0 to 85.8), while that of patients with Stage IV was 8.6 months (95% CI 0 to 23.3), which showed a statistically significant difference (p=0.01). In addition, among patients with Stage IV, the OS of patients who received a palliative treatment (immunotherapy, chemotherapy, or targeted therapy) was 18.4 months, which was higher than the OS of patients without treatment of 4.5 months.

Conclusion

CDC is a highly aggressive form of renal cell carcinoma. Despite most of the treatments, PFS and OS were short, however, there were some long-term survivors, therefore, conduct of additional research on the predictive markers of the several clinical, pathological differences and their treatments will be necessary.

Citations

Citations to this article as recorded by

Collecting Duct Carcinoma: Characteristics and Survival Outcomes From UroCCR Database (CDCSurv UroCCR n°141)
Louis-Pacôme Le Mével, Jean-Christophe Bernhard, Mokrane Yacoub, Thibaut Waeckel, Céline Bazille, Cécile Champy, Maria Mamodaly, Karim Bensalah, Nathalie Rioux-Leclercq, Constance Michel, Ilhem Hergli, Louis Surlemont, Julie Leclerc, Morgan Roupret, Franc
Clinical Genitourinary Cancer.2025; 23(2): 102305. CrossRef
Urothelial Carcinoma of the Renal Pelvis with Synchronous Ipsilateral Collecting Duct Carcinoma: Two Case Reports
Sang Bin Bae, Seong Kuk Yoon, Seo-hee Rha
Journal of the Korean Society of Radiology.2024; 85(1): 222. CrossRef
A curious case: Concurrent collecting duct renal cell carcinoma and upper tract urothelial carcinoma
Adib Rahman, Daniel Matheson, Joanna Perry-Keene, Devang Desai
Urology Case Reports.2024; 54: 102698. CrossRef
Cancer subtype identification by multi-omics clustering based on interpretable feature and latent subspace learning
Tianyi Shi, Xiucai Ye, Dong Huang, Tetsuya Sakurai
Methods.2024; 231: 144. CrossRef
Tumeurs de Bellini et carcinomes médullaires rénaux à l’ère des nouvelles thérapies
Zoé Guillaume, Yves Allory, Edouard Auclin, Claire Gervais, Marie Auvray, Adrien Rochand, Arnaud Mejean, François Audenet, Yann-Alexandre Vano, Stéphane Oudard, Constance Thibault
Bulletin du Cancer.2023; 110(4): 450. CrossRef
Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
Zoé Guillaume, Emeline Colomba, Jonathan Thouvenin, Carolina Saldana, Luca Campedel, Clément Dumont, Brigitte Laguerre, Denis Maillet, Cécile Vicier, Frédéric Rolland, Delphine Borchiellini, Philippe Barthelemy, Laurence Albiges, Edouard Auclin, Matthieu
Cancers.2022; 14(7): 1678. CrossRef
Uncommon malignant renal tumors and atypical presentation of common ones: a guide for radiologists
Benjamin Laguna, Antonio C. Westphalen, C. T. Guimarães, Zhen Whang, Jeff Simko, Ronald Zagoria
Abdominal Radiology.2019; 44(4): 1430. CrossRef
Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors
A. Pinto, M. Garrido, C. Aguado, T. Alonso, P. Gajate, C. Maximiano, I. García-Carbonero, A. Martín, I. Gallegos, J.A. Arranz, J. Puente, E. Grande
Kidney Cancer.2019; 3(3): 177. CrossRef
Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
Meghan Salgia, Jacob Adashek, Paulo Bergerot, Sumanta K. Pal
Kidney Cancer.2017; 1(2): 99. CrossRef
Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas
Gabriel G. Malouf, Eva Compérat, Hui Yao, Roger Mouawad, Veronique Lindner, Nathalie Rioux-leclercq, Virginie Verkarre, Xavier Leroy, Linda Dainese, Marion Classe, Jean-Luc Descotes, Philippe Barthelemy, Mokrane Yacoub, Morgan Rouprêt, Jean-Christophe Ber
Scientific Reports.2016;[Epub] CrossRef
Clinical and computed tomography imaging features of renal medullary carcinoma: A report of six cases
ZHENSHAN SHI, QIAN ZHUANG, RUIXIONG YOU, YUEMING LI, JIAN LI, DAIRONG CAO
Oncology Letters.2016; 11(1): 261. CrossRef
Collecting duct carcinoma of the kidney is associated withCDKN2Adeletion andSLCfamily gene up-regulation
Jianmin Wang, Antonios Papanicolau-Sengos, Sreenivasulu Chintala, Lei Wei, Biao Liu, Qiang Hu, Kiersten Marie Miles, Jeffrey M. Conroy, Sean T. Glenn, Manuela Costantini, Cristina Magi-Galluzzi, Sabina Signoretti, Toni Choueiri, Michele Gallucci, Steno Se
Oncotarget.2016; 7(21): 29901. CrossRef

12,330 View
75 Download
16 Web of Science
12 Crossref

High-Dose-Rate Brachytherapy for the Treatment of Vaginal Intraepithelial Neoplasia: Jin Ho Song, Joo Hwan Lee, Jong Hoon Lee, Jong Sup Park, Sook Hee Hong, Hong Seok Jang, Yeon Sil Kim, Byung Ock Choi, Sei Chul Yoon; Cancer Res Treat. 2014;46(1):74-80. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.74

Abstract PDF PubReader ePub

PURPOSE
Vaginal intraepithelial neoplasia (VAIN), a rare premalignant condition, is difficult to eradicate. We assess the effectiveness of high-dose rate intracavitary brachytherapy (HDR-ICR) in patients with VAIN or carcinoma in situ (CIS) of the vagina after hysterectomy.
MATERIALS AND METHODS
We reviewed 34 patients treated for posthysterectomy VAIN or CIS of the vagina by brachytherapy as the sole treatment. All patients underwent a coloposcopic-directed punch biopsy or had abnormal cytology, at least 3 consecutive times. All patients were treated with a vaginal cylinder applicator. The total radiation dose was mainly 40 Gy in 8 fractions during the periods of 4 weeks at a prescription point of the median 0.2 cm (range, 0 to 0.5 cm) depth from the surface of the vaginal mucosa.
RESULTS
Acute toxicity was minimal. Seven patients had grade 1/2 acute urinary and rectal complications. There were 15 cases of late toxicity, predominantly vaginal mucosal reaction in 12 patients. Of these patients, two patients suffered from grade 3 vaginal stricture and dyspareunia continuously. After a median follow-up time of 48 months (range, 4 to 122 months), there were 2 recurrences and 2 persistent diseases, in which a second-line therapy was needed. The success rate was 88.2%. The average prescription point in failure patients was 1.1 mm from the surface of the vagina compared to an average of 2.6 mm in non-recurrent patients (p=0.097).
CONCLUSION
HDR-ICR is an effective treatment method in VAIN patients. In spite of high cure rates, we should consider issues regarding vaginal toxicity and radiation techniques to reduce the occurrence of failure and toxicity.

Citations

Citations to this article as recorded by

Is robotic-assisted vaginectomy a better choice in vaginal high-grade squamous intraepithelial lesions than conventional laparoscopic surgery?
Yana Liu, Meng Mao, Jing Bai, Mingbo Cai, Qian Wang, Hanlin Fu, Mengling Zhao, Chunfang Wang, Lulu Si, Ruixia Guo
BMC Women's Health.2024;[Epub] CrossRef
Advances in the Treatment of High-Grade Stump Vaginal Intraepithelial Neoplasia after Total Hysterectomy
俐君刘
Advances in Clinical Medicine.2024; 14(04): 1555. CrossRef
Comprehensive evaluation of vaginal intraepithelial neoplasia development after hysterectomy: insights into diagnosis and treatment strategies
Jiahui Wei, Yumei Wu
Archives of Gynecology and Obstetrics.2024; 310(1): 1. CrossRef
Non-Excisional therapeutic modalities in vaginal intraepithelial neoplasia
Gonçalo Freitas, Antónia Costa
European Journal of Obstetrics & Gynecology and Reproductive Biology.2023; 284: 175. CrossRef
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) Consensus State
Vesna Kesic, Xavier Carcopino, Mario Preti, Pedro Vieira-Baptista, Federica Bevilacqua, Jacob Bornstein, Cyrus Chargari, Maggie Cruickshank, Emre Erzeneoglu, Niccolò Gallio, Murat Gultekin, Debra Heller, Elmar Joura, Maria Kyrgiou, Tatjana Madić, François
Journal of Lower Genital Tract Disease.2023; 27(2): 131. CrossRef
The European Society of Gynaecological Oncology (ESGO), the International Society for the Study of Vulvovaginal Disease (ISSVD), the European College for the Study of Vulval Disease (ECSVD), and the European Federation for Colposcopy (EFC) consensus state
Vesna Kesic, Xavier Carcopino, Mario Preti, Pedro Vieira-Baptista, Federica Bevilacqua, Jacob Bornstein, Cyrus Chargari, Maggie Cruickshank, Emre Erzeneoglu, Niccolò Gallio, Murat Gultekin, Debra Heller, Elmar Joura, Maria Kyrgiou, Tatjana Madić, François
International Journal of Gynecological Cancer.2023; 33(4): 446. CrossRef
Analysis of related factors of cervical intraepithelial neoplasia complicated with vaginal intraepithelial neoplasia
Y.Y. Zhang, R. Xia, D. Chen, X. Zhang
Clinical and Translational Oncology.2022; 24(5): 902. CrossRef
Sexual Health Dysfunction After Radiotherapy for Gynecological Cancer: Role of Physical Rehabilitation Including Pelvic Floor Muscle Training
Amelia Barcellini, Mattia Dominoni, Francesca Dal Mas, Helena Biancuzzi, Sara Carla Venturini, Barbara Gardella, Ester Orlandi, Kari Bø
Frontiers in Medicine.2022;[Epub] CrossRef
Clinical outcomes of laser vaporization for vaginal intraepithelial neoplasia – A 20-year retrospective review
Mung Yuen He, Ellen Lok-man Yu, Sze Ki Hui, Yau Lung Fred Kung
European Journal of Obstetrics & Gynecology and Reproductive Biology.2022; 277: 101. CrossRef
Detection of high‐risk human papillomavirus infection and treatment of high‐grade vaginal intraepithelial neoplasia: A single‐institution study
Hyun‐Woong Cho, Jin Hwa Hong, Jae Kwan Lee
International Journal of Gynecology & Obstetrics.2021; 154(2): 227. CrossRef
UK national survey of the management of vaginal intraepithelial neoplasia
Mahalakshmi Gurumurthy, Simon Leeson, John Tidy, Margaret E. Cruickshank
Journal of Obstetrics and Gynaecology.2020; 40(5): 694. CrossRef
Vaginal carcinoma after cervical dysplasia
Mikel Gorostidi, Arantza Lekuona, Arantxa Juaristi, Glauco Baiocchi
International Journal of Gynecological Cancer.2020; 30(2): 265. CrossRef
Management options for vaginal intraepithelial neoplasia
Argirios Rountis, Vasilios Pergialiotis, Paraskevi Tsetsa, Alexandros Rodolakis, Dimitrios Haidopoulos
International Journal of Clinical Practice.2020;[Epub] CrossRef
Effect of Cyclophosphamide Treatment on Central and Effector Memory T Cells in Mice
Marcin Włodarczyk, Elżbieta Ograczyk, Magdalena Kowalewicz-Kulbat, Magdalena Druszczyńska, Wiesława Rudnicka, Marek Fol
International Journal of Toxicology.2018; 37(5): 373. CrossRef
Total vaginectomy for refractory vaginal intraepithelial neoplasia III of the vaginal vault
Ju Hyun Youn, Min Ah Lee, Woong Ju, Seoung Cheol Kim, Yun Hwan Kim
Obstetrics & Gynecology Science.2016; 59(1): 71. CrossRef
Brachytherapy for vaginal intraepithelial neoplasia
Agnieszka Zolciak-Siwinska, Ewelina Gruszczynska, Joanna Jonska-Gmyrek, Anna Kulik, Wojciech Michalski
European Journal of Obstetrics & Gynecology and Reproductive Biology.2015; 194: 73. CrossRef

14,388 View
196 Download
17 Web of Science
16 Crossref

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer: Eun Kyoung Jeon, Sook Hee Hong, Tae Hee Kim, Seung Eun Jung, Ji Chan Park, Hye-Sung Won, Yoon-Ho Ko, Sang Young Rho, Young Seon Hong; Cancer Res Treat. 2011;43(3):148-153. Published online September 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.3.148

Abstract PDF PubReader ePub

PURPOSE
The purpose of this study was to evaluate efficacy and toxicity of irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as second-line treatment after failure of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) for advanced gastric cancer.
MATERIALS AND METHODS
Patients who received modified FOLFOX-4 as first-line treatment and then received sequential modified FOLFIRI for disease progression were included in this study. The modified FOLFIRI regimen consisted of irinotecan 150 mg/m2 in a 90-minute intravenous infusion on day 1, leucovorin (LV) 20 mg/m2 and 5-fluorouracil (5-FU) 400 mg/m2 as a bolus followed by 600 mg/m2 as a 22-hour infusion on days 1 and 2 with the same dose of 5-FU/LV of modified FOLFOX-4 every 2 weeks.
RESULTS
A total of 32 patients received 126 courses of FOLFIRI chemotherapy. No complete response was achieved. Three patients (9.4%; 95% confidence interval [CI], 0 to 20.1%) achieved partial response, whereas 11 (34.4%; 95% CI, 17.0 to 51.8%) patients showed stable disease. Disease control rate (complete response, partial responses and stable diseases) was 43.8% (95% CI, 25.6 to 61.9%) and median follow up duration was 11.3 months (range, 2.23 to 37.9 months). Median time to progression was 2 months (95% CI, 1.49 to 2.51 months), and median overall survival from the start of FOLFIRI was 5.84 months (95% CI, 4.34 to 7.34 months). Toxicities were tolerable.
CONCLUSION
Modified FOLFIRI as second-line chemotherapy after failure of the modified FOLFOX-4 in advanced gastric cancer was tolerable but showed a lower response rate. Further study about retrying 5-FU/LV with irinotecan after failure of the 5-FU/LV combined regimen is necessary in advanced gastric cancer.

Citations

Citations to this article as recorded by

Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
Ana Fernández Montes, Carlos López López, Guillem Argilés Martínez, David Páez López, Ana María López Muñoz, Beatriz García Paredes, David Gutiérrez Abad, Carmen Castañón López, Paula Jiménez Fonseca, Javier Gallego Plazas, María Carmen López Doldán, Eva
The Oncologist.2019; 24(8): e687. CrossRef
Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition
Chinnadurai Mani, Sachin Pai, Cinta Maria Papke, Komaraiah Palle, William H. Gmeiner
Neoplasia.2018; 20(12): 1236. CrossRef
Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer
Zheng Chen, Zhenyu Zhou, Zhigang Hu, Qiaodong Xu, Jie Wang
Oncology Letters.2017;[Epub] CrossRef
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Markus Moehler, Irina Gepfner-Tuma, Annett Maderer, Peter C. Thuss-Patience, Joern Ruessel, Susanna Hegewisch-Becker, Hansjochen Wilke, Salah-Eddin Al-Batran, Mohammad-Reza Rafiyan, Florian Weißinger, Hans-Joachim Schmoll, Frank Kullmann, Ludwig Fischer v
BMC Cancer.2016;[Epub] CrossRef
5-Fluorouracil derivatives: a patent review (2012 – 2014)
Esmeralda Carrillo, Saúl Abenhamar Navarro, Alberto Ramírez, María Ángel García, Carmen Griñán-Lisón, Macarena Perán, Juan Antonio Marchal
Expert Opinion on Therapeutic Patents.2015; 25(10): 1131. CrossRef
Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer
Sung Chul Park, Hoon Jai Chun
The Korean Journal of Gastroenterology.2015; 66(1): 1. CrossRef
Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer
Hye Jung Kwon, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Hae Won Lee, Youn Jung Choi, Jae Hyun Kim
The Korean Journal of Gastroenterology.2015; 66(1): 10. CrossRef
FOLFIRI as Second-line Chemotherapy after Failure of FOLFOX4 in Advanced Colorectal Cancer: A Korean Single-center Experience
Jae Hyun Kim, Seun Ja Park, Moo In Park, Won Moon, Sung Eun Kim, Ki Hwan Ku, Sung Eun Song, Je Hun Kim
The Korean Journal of Gastroenterology.2014; 63(1): 18. CrossRef
5-Fluorouracil derivatives: a patent review
Pablo Álvarez, Juan Antonio Marchal, Houria Boulaiz, Esmeralda Carrillo, Celia Vélez, Fernando Rodríguez-Serrano, Consolación Melguizo, Jose Prados, Roberto Madeddu, Antonia Aranega
Expert Opinion on Therapeutic Patents.2012; 22(2): 107. CrossRef
Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang
Cancer Research and Treatment.2012; 44(4): 235. CrossRef
Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer
JUNG HAN KIM, HYEONG SU KIM, A RUM HAN, IN HO MOH, DOO CHEOL CHUNG, DAE RO CHOI, HYUN JOO JANG, JIN BAE KIM, DAE HYUN YANG, SOON IL LEE, DAE YOUNG ZANG
Oncology Letters.2012; 4(4): 751. CrossRef

12,047 View
83 Download
12 Crossref

Case Report

Unusual Presentation of Large B Cell Lymphoma- Bone and Stomach- Treated with Autologous Transplantation: Bokyung Kim, Sung Yong Oh, Suee Lee, Hyuk-Chan Kwon, Sung-Hyun Kim, Sook Hee Hong, Sung-Soo Kim, Hyo-Jin Kim; Cancer Res Treat. 2007;39(4):181-184. Published online December 31, 2007; DOI: https://doi.org/10.4143/crt.2007.39.4.181

Abstract PDF PubReader ePub: Extranodal presentation of diffuse large B cell lymphoma (DLBL) is frequently observed in the gastrointestinal tract, CNS, bone, testes and liver. However, the simultaneous detection of multiple extranodal involvement at presentation is quite an uncommon occurrence. In this study, we report on a patient with an uncommon presentation of DLBL, and he had symptoms of left knee joint pain and hematemesis, characterized by bone and stomach involvement. Computed tomography and fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning revealed a rapid, extensive spread to the bones and soft tissues. Subsequent histopathological examination verified the bony and gastric CD20-positive DLBL localization. We diagnosed this case as DLBL of stage IV with an international prognostic index of 3, and classified him into the high intermediate risk group. This patient was treated via chemotherapy with an R-CHOP regimen. After achieving a partial response, the patient received autologous peripheral blood stem cell transplantation. The patient attained partial remission, as shown on the FDG-PET scan, and he displayed improvement of his left femur pain.

9,352 View
50 Download

Original Articles

Clinical Characteristics of Primary Peritoneal Carcinoma: Sang Young Roh, Sook Hee Hong, Yoon Ho Ko, Tae Hee Kim, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, In Sook Woo, Jin Hyoung Kang, Young Seon Hong, Kyung Shik Lee; Cancer Res Treat. 2007;39(2):65-68. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.65

Abstract PDF PubReader ePub

Purpose

The goal of this study was to determine the clinical and therapeutic characteristics of women with a primary peritoneal carcinoma (PPC).

Materials and Methods

A retrospective clinical study was conducted to evaluate 22 women diagnosed with a PPC from 1993 to 2007 at the Hospitals of The Catholic University of Korea. Diagnoses were based on the Gynecologic Oncology Group criteria and clinical data. We collected patient clinicopathological data including age, presenting symptoms, pretreatment CA-125 values (U/ml), clinical stage (based on the FIGO stage), performance status (using the Eastern Cooperative Oncology Group scale), whether cytoreductive surgery was optimal or not, types of chemotherapy and response to treatment. We evaluated the clinical characteristics and response to treatment, time to treatment failure and overall survival.

Results

The median overall survival of all patients was 23.1 months. The estimated 3-year survival rate was 29% (SE, 13%). The response rate to first-line platinum-based chemotherapy was 79% and the median time to treatment failure was 9.9 months (95% confidence interval, 1.38~18.4 months). By univariate and multivariate analysis, performance status was the only significant factor associated with overall survival (p<0.05).

Conclusion

We evaluated the clinical characteristics and treatment response of patients with a primary peritoneal carcinoma. Our results showed that it is possible to achieve long-term survival in patients with PPC. A further clinical study is to need to establish clinical characteristics and treatment outcomes.

Citations

Citations to this article as recorded by

Incidentally Diagnosed Low-Grade Primary Peritoneal Serous Carcinoma Within the Umbilical Hernia Sac in a Male: A Report of an Extremely Rare Case and Review of the Literature
Samer Ganam, Ayesha Khan, Nicole Riddle, Joseph A Sujka, Christopher G DuCoin
Cureus.2024;[Epub] CrossRef
Primary peritoneal serous carcinoma – A rare case report
Pradnya Neelakanta Reddy, Eugene J S D'Souza, Avinash Anand
IP Journal of Diagnostic Pathology and Oncology.2024; 9(4): 244. CrossRef
Primary peritoneal high-grade serous carcinoma in a man: A case report
Abdelali Guellil, Rachid Jabi, Mohamed Yassine Mabrouk, Laila Bouzayan, Abdelali Merhoum, Gérald Del Gallo, Claire Godart, Mohammed Bouziane
Annals of Medicine and Surgery.2022; 77: 103605. CrossRef
Primary Peritoneal Carcinoma: A Rare Malignancy Presenting a Diagnostic Challenge
Mariam Shabbir, Sonu Sahni, Meena Ahluwalia, Raji Ayinla
Cureus.2022;[Epub] CrossRef
A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide
Shunichi Kawamura, Toshio Kubo, Kenji Takada, Ryota Sunami, Sachi Okawa, Yoshitaka Iwamoto, Atsuko Hirabae, Akihiko Taniguchi, Yoshinobu Maeda, Katsuyuki Kiura, Masahiro Tabata
International Cancer Conference Journal.2021; 10(3): 197. CrossRef
Primary peritoneal mucinous cystadenocarcinoma mimicking possible recurrent ovarian mucinous cystadenoma: coincidental pathology or a spectrum of disease?
Claire Filippini, Sarah Smyth, Hooman Soleymani Majd, Catherine Johnson
BMJ Case Reports.2021; 14(7): e242478. CrossRef
Imaging features of primary peritoneal serous carcinoma: A case report
Ji Soo Oh, Beum Jin Kim, Myoung Jin Ju, Eun Ae Yoo
Radiology Case Reports.2020; 15(7): 978. CrossRef
Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases
Mingming Sun, Lingjie Bao, Haoran Shen, Min Ji, Liangqing Yao, Xiaofang Yi, Wei Jiang
Taiwanese Journal of Obstetrics and Gynecology.2019; 58(5): 626. CrossRef
Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma
Jin Wook Lee, Eun Taek Park
The Korean Journal of Pancreas and Biliary Tract.2018; 23(2): 54. CrossRef
Inguinal Lymph Node Metastasis of a Primary Serous Papillary Carcinoma of the Peritoneum One Year after CRS and HIPEC
Shadi Katou, Mathilde Feist, Wieland Raue, Johann Pratschke, Beate Rau, Andreas Brandl
Visceral Medicine.2018; 34(4): 307. CrossRef
Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma
Dong Mi, Yuexiang Zhang
The International Journal of Biological Markers.2018; 33(4): 395. CrossRef
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review
Jingping Yuan, Liang He, Bing Han, Yan Li
World Journal of Surgical Oncology.2017;[Epub] CrossRef
An unusual cancer involving the rectum: two cases of localized primary peritoneal carcinoma mimicking rectal carcinoma
Jinnie S. Y. Pang, Liying Yang, Ghee Kheng Chew, Min Hoe Chew
International Journal of Colorectal Disease.2016; 31(3): 717. CrossRef
Primary peritoneal serous carcinoma, an extremely rare malignancy: A case report and review of the literature
WOO-SUNG YUN, JUNG-MIN BAE
Oncology Letters.2016; 11(6): 4063. CrossRef
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
Lauren Patterson Cobb, Stephanie Gaillard, Yihong Wang, Ie-Ming Shih, Angeles Alvarez Secord
Gynecologic Oncology Research and Practice.2015;[Epub] CrossRef
Amylase-Producing Primary Peritoneal Carcinoma
Ji-Woon Lee, Sang-Gon Park
The Korean Journal of Medicine.2015; 89(3): 358. CrossRef
Solitary primary peritoneal carcinoma arising from the omentum
Yi-Jou Tai, Ming-Chieh Lin, Chin-Jui Wu, Chi-An Chen, Wen-Fang Cheng
Taiwanese Journal of Obstetrics and Gynecology.2014; 53(2): 256. CrossRef
Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
Skyler B. Johnson, Joann I. Prisciandaro, Jessica Zhou, Scott W. Hadley, R. Kevin Reynolds, Shruti Jolly
Journal of Applied Clinical Medical Physics.2014; 15(1): 202. CrossRef
Embryonic natural orifice transumbilical endoscopic surgery (E-NOTES) for adnexal tumors
Myong Cheol Lim, Tae-Joong Kim, Sokbom Kang, Duk-Soo Bae, Sang-Yoon Park, Sang-Soo Seo
Surgical Endoscopy.2009; 23(11): 2445. CrossRef

10,718 View
93 Download
19 Crossref

Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma: Sook Hee Hong, Young Seon Hong, In Sook Woo, Yoon Ho Koh, Sang Young Rho, Ji Yean Peak, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, Ji Chan Park, Jong Wook Lee, Woo Sung Min, Chun Choo Kim; Cancer Res Treat. 2007;39(2):54-60. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.54

Abstract PDF PubReader ePub

Purpose

High-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) have been used for the treatment of clinically aggressive non-Hodgkin's lymphoma (NHL). However, the superiority of specific conditioning regimens has not yet been established. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation (TBI), and the use of Ara-C and melphalan (TAM) for clinically aggressive NHL.

Materials and Methods

Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI with a dose of 12 Gy over 3 days, and were administered 9 g/m² Ara-C and 100 mg/m² melphalan followed by autologous peripheral blood stem Cell Transplantation at the Catholic Hematopoietic Stem cell transplantation Center Korea. Patients that responded to first line chemotherapy and achieved complete remission (CR), or were in a first sensitive relapse were defined as having less advanced disease, while the other patients were defined as having more advanced disease.

Results

Objective responses were obtained in 24 of 31 patients (77.4%), comprising complete remission in 19 patients (61.3%) and partial remission in 5 (16.1%) patients. The median follow-up time was 28 months (range 1~62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3% and 47.3%, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3% and 22.5 %, respectively (p=0.006). Early (within the first 100 days) treatment-related mortality occurred in 3 (9.7%) patients. Of the 31 total patients, 15 (48.4%) developed grade 3 mucositis, 22 (70.9%) developed neutropenic fever, and two (6.5%) developed interstitial pneumonia syndrome>grade 3.

Conclusion

The modified TAM conditioning regimen and ASCT appear to be a feasible treatment regimen for clinically aggressive NHL, particularly for patients with less advanced disease.

Citations

Citations to this article as recorded by

Comparison of regional arterial chemotherapy and systemic intravenous chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis
Chengqing Li, Wenyi Guo, Shihong Chen, Jianwei Xu, Feng Li, Lei Wang
Journal of Pancreatology.2022; 5(2): 49. CrossRef

9,950 View
56 Download
1 Crossref

Expression Pattern and Prognostic Correlation of BAG - 1 Protein in Breast Cancer: Se Hoon Cho, Dae Young Lee, Byung Jin Kim, Sook Hee Hong; J Korean Cancer Assoc. 2000;32(1):60-67.

Abstract PDF: PURPOSE
The objective of this study was to understand the expression of BAG-1 in the human breast cancer.
MATERIALS AND METHODS
We studied its expression in one hundred and thirteen patients diagnosed with breast cancer in Dong-A university hospital between 1992 and 1996 by performing immunohistochemical staining with BAG-1 monoclonal antibody.
RESULTS
Of the 113 breast carcinoma examined, 62.0% were positive for BAG-1 cyto- plasmic expression, 28.0% were positive for nuclear BAG-1 expression and 9.7% were positive for both BAG-1 cytoplasmic and nuclear expression. The higher histologic grade was correlated with the higher cytoplasmic expression (p<0.05). Except for histologic grade, no correlation was observed between BAG-1 expression and conventional prognostic factors such as age, menopausal status, metastatic status of the axillary lymh nodes, cathepsin-D, p53, C-erbB-2, DNA ploidy, S-phase fraction, PCNA (proliferating cell nuclear antigen). CONCLUSION: The high histologic grade was found to correlate with positive BAG-1 cyto- plasmic staining which did not correlate with conventional prognostic factors. Our data indicate that furthermore investigation is warranted to define the role of BAG-1 as an meaningful prognostic factor in patients with newly diagnosed breast cancer.

2,935 View
17 Download

Expression of Multidrug Resistance P-Glycoprotein in Breast Carcinoma: Sung Sik Kang, Se Heon Cho, Sang Soon Kim, Jin Sook Jung, Sook Hee Hong; J Korean Cancer Assoc. 1994;26(6):912-926.

Abstract PDF: In 38 women with breast carcinoma who had locally advanced cancer without distant metastasis, the expression of P-glycoprotein was evaluated, using JSB-1 monoclonal antibody by ABC-immunoperoxidase method, P-glycoprotein was detected in 35 of 38 tumor samples(91.4%). Result were expressed in a semiguantitative manner, taking into account the number of posi- tive tumor cells(N index) and the specific staining index(I index). The frequencies of higher expression(N+I+2 or I+3) were detected in 0% of grade I, 33% of grade II and 90.9% of grade III in infiltrating duct carcinoma. Recurred cases were 4 out of 38(10.5%), of which 3 cases showed high histologic grade and more advanced stage with strong P-glycoprotein expression (N+I+3). Strong P-glycoprotein-positive staining in a majority of tumor cells(N-/I+3) was significantly correlated with histoiogic group with poor prognosis hi#gh histologic grade and recurrence. Thus, the pretreatment evaluation of P-glycoprotein expression may be of prognostic value in patients with locally advanced breast cancer. The possiblity that Mdrl enhances the invasiveness of cancer was suggested.

2,783 View
14 Download

Prognostic Significance of Proliferating Cell Nuclear Antigen ( PCNA ) Expression in Patients with Colorectal Carcinoma: Il Kwon Jung, Hong Jo Choi, Sang Soon Kim, Sook Hee Hong; J Korean Cancer Assoc. 1995;27(4):550-559.

Abstract PDF: Proliferating cell nuclear antigen(PCNA) is an auxiliary protein of DNA polymerase 8 and is considered to correlate with the proliferative state of cells. If such a biologic marker in colorectal cancer tissue correiates with recurrence and poor survival, it would offer a rationale for planning aggressive adjuvant therapy. Authors investigated the prognostic significance of proliferative activity in cancer cells in patients with colorectal carcinoma using PCNA immunohistochemical analysis. An anti-PCNA monoclonal antibody (PC 10) was used to measure proliferation indices in neoplastic colorectal tissues of 61 patients with the different clinical outcomes. The correlations of PCNA labeling index (PCNA LI) with various clinicopathologic factors, recurrence and prognosis were studied. The results obtained were summarized as follows; 1) The PCNA LI become higher as the histologic differentiation decreased and the Dukes stage increased, both of which were statistically significant (p=0.0133 and 0.0001, respectively). 2) The rate of disease recurrence after curative resection (53 cases) was significantly higher in patients with high PCNA LI (PCNA LI>=50) as compared with those with low PCNA LI (PCNA LI<50) (44.4% vs. 14.3%, p= 0.022). 3) In patients with high PCNA LI, prognosis (2-year survival) was significantly poorer than in those with a low index (31.8% vs. 58.6%, p<0.05). As a result of this study, PCNA labeling index as determined by PCNA immuno- histochemical analysis is suggested to be correlated well with the histologic differentiation and tumor stage and to be an effective predictor in colorectal cancer. The PCNA analysis for biologic heterogeneity of patients with colorectal cancer may be useful in the prognostic grouping of patients and planning prophylactic therapy.

3,364 View
23 Download

First
Prev
Page of 1
Next
Last

Search